-
Posted by
Two Blokes May 21 -
Filed in
Stock
-
0 views
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue. Sanofi partnership brings immediate cash, future royalties, and potential milestone payments from pipeline programs, strengthening Novavax's financial outlook.
